Gland Surgery, an esteemed journal published by AME PUBLISHING COMPANY, is at the forefront of surgical research, particularly focusing on advancements in gland-related surgeries and their clinical implications. With an ISSN of 2227-684X and an E-ISSN of 2227-8575, this open-access journal provides a platform for disseminating high-quality research and insights into the intricate aspects of surgical practices, ranking in the Q2 category in Surgery as of 2023. As evidenced by its Scopus ranking at #153 out of 551 in the Medicine_Surgery field, Gland Surgery delivers valuable contributions to the global medical community, promoting the exchange of knowledge and innovative techniques. Operating from Hong Kong, China, and converging its excellence from 2016 to 2024, the journal is a critical resource for researchers, clinicians, and students keen on exploring the latest developments in the field. By fostering an open dialogue among professionals, Gland Surgery is accessible to a diverse audience seeking to enhance their understanding and practice in gland surgery.

INTERNATIONAL JOURNAL OF HYPERTHERMIA, published by Taylor & Francis Ltd, is a leading peer-reviewed journal dedicated to advancing the field of hyperthermia and its applications in medical science, particularly within cancer research and related disciplines. With an ISSN of 0265-6736 and an E-ISSN of 1464-5157, this journal has been a vital resource since its establishment in 1985, offering a platform for innovative research and clinical applications aimed at improving treatment outcomes. The journal is recognized with a Q2 category ranking in several fields, including Cancer Research and Physiological Medicine, reflecting its significant contribution to scientific knowledge and clinical practices. Furthermore, it has been Open Access since 2019, ensuring that cutting-edge research is accessible to a global audience. By facilitating the exchange of ideas and fostering collaborations among researchers, professionals, and students, the INTERNATIONAL JOURNAL OF HYPERTHERMIA serves as an essential resource in the quest to exploit hyperthermia’s full potential in therapeutic settings.

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY is a pivotal publication in the field of gynecological oncology, dedicated to advancing research and clinical practices. Established in 1980 and published by MRE PRESS, this journal serves as a platform for disseminating high-quality research, reviews, and case studies pertaining to the diagnosis and treatment of gynecological cancers. Although the journal currently operates without an open access option, it remains a valuable resource for professionals seeking to stay abreast of the latest developments and findings within the field. The journal is indexed in both Scopus and other reputable databases, contributing significantly to the ongoing discourse in medicine with a particular focus on obstetrics, gynecology, and oncology, although it has seen a discontinuation in coverage by Scopus post-2021. With an emphasis on rigorous peer-review and scholarly integrity, the EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY continues to play an essential role in fostering knowledge and innovation among researchers, clinicians, and students committed to improving patient outcomes in gynecological health.

Investigative and Clinical Urology is an esteemed open-access journal dedicated to advancing research and clinical practice in the field of urology. Published by the Korean Urological Association, this journal serves as a crucial platform for sharing innovative findings and discussions on urological science, treatments, and technologies. With an ISSN of 2466-0493 and an E-ISSN of 2466-054X, it has established its presence in the academic community since transitioning to open access in 2016. Positioned in the Q2 quartile of urology journals for 2023 and ranked 39th out of 120 in Scopus's urology category, it reflects a strong impact in the field with a 67th percentile ranking. This journal not only facilitates broad accessibility to high-quality research but also fosters collaboration and dialogue among researchers, professionals, and students interested in the latest advancements in urology. Operating from Seoul, South Korea, Investigative and Clinical Urology remains a pivotal resource for anyone seeking to enhance their understanding and practice in urological medicine.

Gynecologic Oncology Reports is a pivotal interdisciplinary journal published by Elsevier Science Inc. that has been dedicated to advancing the understanding of women's health since its inception in 2014. This Open Access journal, available to a global audience, facilitates the dissemination of high-quality research in the fields of gynecology and oncology, allowing for the free exchange of knowledge and fostering collaboration among researchers, clinicians, and students. With an impact factor reflective of its commitment to clinical relevance, Gynecologic Oncology Reports holds a Q3 ranking in both obstetrics and gynecology as well as oncology categories, contributing to its visibility and the prestige of published work. Situated in the Netherlands and operating within an open-access framework, it ensures that critical findings and advancements reach a broad readership. The journal serves as a vital resource for those aiming to stay at the forefront of gynecologic oncology, promoting improved patient outcomes through cutting-edge research. As it converges towards its 10th anniversary in 2024, Gynecologic Oncology Reports continues to be an essential platform for scholarly communication in this important field.

Urologic Oncology - Seminars and Original Investigations is a premier journal published by Elsevier Science Inc, dedicated to advancing the field of urologic oncology through high-quality, peer-reviewed research and insightful scholarly discussions. With an ISSN of 1078-1439 and an E-ISSN of 1873-2496, this journal has established itself as a vital resource for professionals, researchers, and students alike since its inception in 1995. Currently holding a Q2 ranking in Oncology and a prestigious Q1 in Urology for 2023, it ranks 28th out of 120 in Urology and 177th out of 404 in Oncology within Scopus, underscoring its relevance and impact in these critical fields. While the journal operates under a subscription model, it continues to deliver compelling and transformative research aimed at enhancing patient outcomes in urologic oncology. With a focus on innovative therapies, diagnostic advancements, and clinical trials, the journal contributes significantly to ongoing dialogue and development in urologic health care.

Blood and Lymphatic Cancer-Targets and Therapy, published by DOVE MEDICAL PRESS LTD, is a vital open-access journal that has been disseminating crucial research and findings in the field of hematology and oncology since 2011. With its ISSN 1179-9889, this journal focuses on the latest therapeutic targets and innovative treatment strategies for blood and lymphatic cancers, contributing significantly to the advancement of knowledge and practice in this specialized area. Designed for researchers, healthcare professionals, and students alike, Blood and Lymphatic Cancer-Targets and Therapy aims to foster a deeper understanding of cancer biology and promote collaborative efforts leading to novel therapeutic interventions. The open-access model ensures that research findings are readily accessible to a global audience, underscoring the journal's commitment to enhancing patient care and fostering educational growth in the cancer domain.

Urology Annals, published by Wolters Kluwer Medknow Publications, is a premier open-access journal dedicated to advancing the field of urology through high-quality research and clinical insights. Established in India in 2009, this journal serves as a vital platform for communication among urologists, researchers, and medical professionals, aiming to enhance understanding and innovation in urological sciences. With an ISSN of 0974-7796 and an E-ISSN of 0974-7834, the journal offers unrestricted access to its content, fostering knowledge dissemination and collaboration across the global medical community. Currently ranked in the Q3 category within urology and holding a Scopus rank of #79/120, Urology Annals showcases significant contributions that align with its mission to publish original research, reviews, and case reports that address contemporary challenges in urology. The journal's ongoing commitment to remaining a leading resource in the field is reflected through its convergence of years from 2010 to 2024, ensuring that it stays at the forefront of the latest urological advancements.

BMC Gastroenterology is a premier open-access journal published by BMC, dedicated to disseminating high-quality research in the field of gastroenterology. Established in 2001 and headquartered in the United Kingdom, this journal aims to enhance the understanding of gastrointestinal disorders through innovative research, reviews, and clinical studies. With an impressive impact factor and ranking within the Q2 category in gastroenterology and miscellaneous medicine for 2023, BMC Gastroenterology plays a critical role in advancing knowledge and practices in the field. The journal's commitment to open access ensures that researchers, professionals, and students worldwide can freely access and share vital findings and insights. Encouraging collaboration and knowledge transfer, BMC Gastroenterology is an essential resource for those dedicated to improving gastrointestinal health and outcomes.

Tumori Journal is a distinguished publication in the field of oncology, dedicated to advancing the understanding and treatment of cancer since its inception in 1946. Published by SAGE Publications Ltd, this Italian journal serves as a pivotal platform for researchers, clinicians, and academicians to disseminate cutting-edge findings in cancer research and related areas of medicine. With an impressive record of contributions spanning multiple decades, Tumori Journal aims to foster collaboration and dialogue among professionals in the oncology community. Although classified in the Q4 category for Cancer Research and the Q3 category for both Medicine (miscellaneous) and Oncology as of 2023, the journal continues to draw interest with its rigorous peer-review process and commitment to quality. Researchers are encouraged to explore innovative methodologies and share impactful clinical insights through the journal, which also ranks within the top tiers of Scopus metrics for oncology and cancer research domains. With a growing emphasis on accessible research, Tumori Journal remains an essential resource in the continuous fight against cancer.